Compounded Tirzepatide: What It Is, Who Can Prescribe It, Dosing, Cost and 2026 Legal Status

Key takeaways

• Compounded tirzepatide is the active ingredient of Mounjaro and Zepbound, dissolved into a multi-dose vial by a pharmacy instead of filled into a pen by the manufacturer. FDA has never reviewed any compounded version; every number on this page comes from trials of the brand.
• The brand trials are strong: in SURMOUNT-1, adults with obesity lost 15.0 to 20.9 percent of their body weight over 72 weeks on 5 to 15 mg, against 3.1 percent on placebo, and tirzepatide beat semaglutide head to head in SURMOUNT-5. No trial has tested a compounded product, and no phase 3 trial has tested a dose below 2.5 mg.
• Dosing follows the Zepbound label: 2.5 mg weekly for four weeks, then steps of 2.5 mg at least four weeks apart, up to 15 mg. With a vial, every dose is converted into syringe units from the concentration on your label, which is where the documented overdoses come from.
• In October 2026 compounded tirzepatide costs about $180 to $300 a month through telehealth; brand Zepbound vials cost $299 to $449 through the manufacturer's self-pay program. The gap that drove compounding in 2024 has mostly closed.
• The legal window is narrow. FDA declared the tirzepatide shortage over on December 19, 2024; since then a compounded version is legal only for a patient with a documented clinical need the approved product cannot meet. FDA sent 55 warning letters to telehealth companies in 2026 and has proposed keeping tirzepatide off the 503B list.

Tirzepatide (compounded) at a glance

Also called

compounded tirzepatide, compound tirzepatide, tirzepatide vial, Mounjaro (brand), Zepbound (brand), LY3298176

Class

Dual GIP and GLP-1 receptor agonist; a synthetic 39-amino-acid peptide with a fatty-acid side chain that gives it a half-life of about five days

Route

Subcutaneous injection once weekly; compounded versions are drawn from a multi-dose vial with an insulin syringe

FDA status

Tirzepatide is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (weight management and obstructive sleep apnea). Compounded tirzepatide is an unapproved copy that FDA has never reviewed; since the shortage was declared resolved on December 19, 2024, it may be compounded only for an individual patient with a documented clinical need the approved product cannot meet.

FDA Category 2 (compounding restricted)

No

Available by prescription (US)

Brand Zepbound and Mounjaro by prescription; compounded only for a documented individual clinical need

Best-studied use

Chronic weight management in adults with obesity or overweight (SURMOUNT trials), type 2 diabetes (SURPASS trials) and obstructive sleep apnea in adults with obesity; the compounded product itself has no trials

Typical monthly cost (telehealth, 2026)

$180 to $300 a month for compounded tirzepatide through telehealth (full range $99 to $399); brand Zepbound vials $299 to $449 a month through the manufacturer's self-pay program

What compounded tirzepatide is

Tirzepatide is a synthetic peptide of 39 amino acids built on the sequence of the gut hormone GIP, with a fatty-acid side chain that binds albumin and gives it a half-life of about five days (Zepbound label). Eli Lilly sells it as Mounjaro, approved for type 2 diabetes in 2022, and as Zepbound, approved for chronic weight management in 2023 and for obstructive sleep apnea in adults with obesity in 2024. Those are the only tirzepatide products FDA has ever reviewed.

"Compounded tirzepatide" is the same active ingredient bought as a bulk powder, dissolved and filled into vials by a pharmacy. The pharmacy, not FDA, sets the concentration, the diluent, the preservative and the beyond-use date, and no regulator tests the finished vial. During the 2024 shortage this was how most telehealth weight-loss programs supplied the drug; many still do.

503A versus 503B

A 503A pharmacy is state-licensed and compounds for a named patient on a prescription; FDA does not review its products. A 503B outsourcing facility registers with FDA, follows manufacturing-style quality rules, is inspected, and may make batches without patient-specific prescriptions, but only from substances on FDA's 503B list or drugs in shortage. On May 1, 2026, FDA proposed not to include tirzepatide, semaglutide or liraglutide on that list (Federal Register, May 2026). If finalized, outsourcing facilities would have no basis to make tirzepatide, leaving 503A compounding, one patient at a time, as the only lane.

How tirzepatide works

GIP and GLP-1 are incretin hormones released by the gut after a meal, and tirzepatide activates both receptors. Through the GLP-1 receptor it increases insulin release when glucose is high, suppresses glucagon, slows stomach emptying and reduces appetite; the GIP activity adds to the weight and glucose effects. In the phase 2 trial the dual agonist lowered HbA1c and weight more than dulaglutide, a GLP-1-only comparator (Frias 2018). People describe eating less without trying and losing interest in food; the same slowing of the stomach causes the nausea, reflux and constipation covered in the safety article. A compounded vial works no differently from a pen, provided it contains what its label says. That qualifier is the whole issue.

What the evidence actually shows

Everything known about tirzepatide comes from trials of the brand: unusually strong evidence for a weight-loss drug, earned by a verified product at fixed doses.

Tirzepatide claims graded by the evidence; every trial used the approved product

Claim	Grade	What the evidence shows	Sources
Large weight loss in adults with obesity, without diabetes	A	SURMOUNT-1: 2,539 adults, 72 weeks. -15.0% (5 mg), -19.5% (10 mg) and -20.9% (15 mg) versus -3.1% on placebo; 57% of the 15 mg group lost 20% or more, against 3%.	Jastreboff 2022
Weight loss in obesity with type 2 diabetes	A	SURMOUNT-2: 938 adults, 72 weeks. -12.8% (10 mg) and -14.7% (15 mg) versus -3.2% on placebo; smaller than without diabetes, as with every GLP-1 drug.	Garvey 2023
More weight loss than semaglutide	A	SURMOUNT-5: 751 adults with obesity, 72 weeks, open label. -20.2% on tirzepatide (10 or 15 mg) versus -13.7% on semaglutide (1.7 or 2.4 mg). In type 2 diabetes (SURPASS-2, 40 weeks), tirzepatide 5 to 15 mg beat semaglutide 1 mg on HbA1c and weight.	Aronne 2025; Frías 2021
The loss holds for three years and delays diabetes	A	SURMOUNT-1 extension, 1,032 adults with obesity and prediabetes: -12.3% to -19.7% at 176 weeks versus -1.3% on placebo; type 2 diabetes diagnosed in 1.3% versus 13.3%.	Jastreboff 2025
The weight stays off after stopping	D	The opposite is documented. SURMOUNT-4: after 36 weeks on 10 or 15 mg (-20.9%), those switched to placebo regained 14.0% within a year while those who continued lost a further 5.5%; only 16.6% of the placebo group kept at least 80% of their loss.	Aronne 2024
Doses under 2.5 mg ('microdosing') work	C	One trial of a lower dose exists: phase 2, type 2 diabetes, where 1 mg weekly for 26 weeks lowered HbA1c by 1.06 points and weight by about 0.9 kg, versus 11.3 kg at 15 mg. No phase 3 trial has tested less than 2.5 mg, which the label says is not a maintenance dose.	Frias 2018; Zepbound label
Compounded tirzepatide produces the same results as Zepbound	D	No trial of any compounded tirzepatide product exists. The result depends on the vial containing the labeled amount and on the dose being drawn correctly; FDA verifies neither.	FDA GLP-1 concerns page
Compounded versions are as safe as the brand	D	In FDA's adverse-event database (2018 to 2024), reports involving compounded GLP-1 drugs had far higher odds of preparation errors, contamination and hospitalization than reports involving approved products. FDA had logged more than 730 reports for compounded tirzepatide by May 31, 2026, and has described vial overdoses of 5 to 20 times the intended dose.	McCall 2026; FDA GLP-1 concerns page; FDA dosing-error alert 2024

Three things in that table matter for anyone paying for a vial. The dose-response is real: 5 mg gave about three-quarters of the 15 mg effect in SURMOUNT-1, and below 2.5 mg there is a single small data point. The results are for continued treatment: SURMOUNT-4 shows most of the weight returning within a year of stopping, so a program that prices the first month low and maintenance high is pricing the part that matters. And the trials excluded people a telehealth form may not: pregnancy, a personal or family history of medullary thyroid carcinoma, prior pancreatitis and current insulin or GLP-1 use, in adults with a BMI of 30 or more, or 27 or more with a weight-related condition.

Who can prescribe compounded tirzepatide

Any clinician with prescribing authority who is licensed in the state where you are located at the time of the visit: a physician, or a nurse practitioner or physician assistant under that state's rules. Tirzepatide is not a controlled substance, so the prescription can be written through telehealth, which is why national programs list the states they serve.

Since the shortage ended, a prescription for the compounded version needs one more thing: the prescriber must document why the approved product cannot meet your clinical need, for instance an allergy to an excipient in Zepbound or a need for a strength the manufacturer does not make. FDA has said that price or commercial availability alone is not such a need, and that adding an ingredient such as a vitamin without a clinical rationale does not create one; the legal tracker has the detail.

A legitimate prescription and label look like this:

• A named prescriber licensed in your state, after an evaluation covering weight history, medications, pregnancy status, thyroid, pancreatitis and mental health, not a questionnaire that ends in a shopping cart.
• A prescription that reads like one: tirzepatide, the concentration in mg per mL, the vial volume, the dose in mg and the units to draw, once weekly.
• A pharmacy label naming a state-licensed pharmacy or FDA-registered 503B facility, with lot number, beyond-use date, storage directions and the concentration on the vial itself.
• The drug alone, or with a stated, justified additive, and not labeled with the telehealth company's brand as if the company compounded it; FDA's 2026 letters objected to exactly that (Foley 2026).
• Follow-up: someone who adjusts the dose and knows what to do when side effects are severe.

Dosing: the label schedule, and how vial dosing in units works

The label starts everyone at 2.5 mg once a week for four weeks, then 5 mg; further increases are in 2.5 mg steps, each after at least four weeks, to 7.5, 10, 12.5 and 15 mg. Maintenance doses for weight management are 5, 10 or 15 mg, 2.5 mg is not approved for maintenance, 15 mg is the maximum, and a missed dose can be taken within four days (Zepbound label). The full titration table, the units table and the missed-dose rules are in the tirzepatide dosage chart.

With a pen, the dose is the pen. With a vial, the dose is a volume that depends on the concentration. On a U-100 insulin syringe 100 units equal 1 mL, so:

units = dose in mg ÷ concentration in mg per mL × 100

Take a vial labeled 10 mg per mL and a prescribed dose of 5 mg: 5 ÷ 10 = 0.5 mL, and 0.5 × 100 = 50 units. The same 5 mg from a 5 mg per mL vial is 1 mL, or 100 units, a full syringe; from a 20 mg per mL vial it is 0.25 mL, or 25 units. Zepbound's own multi-dose vials show how wide the range runs: 4.17 to 25 mg per mL, so that every dose is the same 0.6 mL (Zepbound label).

The documented overdoses come from reading a dose written in mg as units, reusing the units that were right for the previous vial after the pharmacy changed the concentration, and mistaking a syringe's unit marks for mL. FDA's 2024 alert on compounded injectable semaglutide described patients drawing 5 to 20 times their intended dose from multi-dose vials, clinicians miscalculating by 5 to 10 times, and hospitalizations (FDA dosing-error alert 2024); the arithmetic for tirzepatide is identical. Run every new vial through the peptide calculator, compare with the label, and call the pharmacy if they disagree.

Cost in October 2026, and why the gap has narrowed

The figures are from our peptide therapy cost guide, collected October 9, 2026. In 2024 a brand pen cost four figures and a compounded vial a few hundred dollars; that gap, with the shortage, built the compounded GLP-1 market. Since then the manufacturer has sold vials direct to cash patients, and the November 2025 federal pricing agreement pushed prices down again. At 2.5 and 5 mg the compounded saving now runs from nothing to about $200 a month; at 10 to 15 mg it is roughly $100 to $200, and the compounded prices at those doses are themselves above the headline rates. Compounded prescriptions are cash only; brand tirzepatide may be covered for obesity and is widely covered for type 2 diabetes.

Risks specific to compounded tirzepatide

The drug's own risks, from gastrointestinal effects to pancreatitis, gallbladder disease and the boxed thyroid warning, are the same from a pen or a vial; the safety article has the label's frequency table. The compounded product adds five of its own.

1. Dosing errors in units, covered above: the risk with the most documented harm, and it exists only because a vial requires arithmetic.
2. Unverified potency and sterility. No one tests the vial you receive. In FDA's adverse-event reporting system (2018 to 2024), reports involving compounded GLP-1 products had 49 times the odds of a preparation error, 19 times the odds of contamination and 2.4 times the odds of hospitalization compared with reports involving approved products; the authors note that reporting data cannot prove cause (McCall 2026).
3. The adverse-event count. As of May 31, 2026, FDA had received 990 reports involving compounded semaglutide and more than 730 involving compounded tirzepatide, while noting that reports do not establish causation and probably undercount, because many pharmacies are not required to report (FDA GLP-1 concerns page), (Drug Discovery and Development 2026).
4. Additives. Some vials include vitamins or other ingredients; no trial has tested any such mixture, and FDA says an added ingredient without a clinical rationale does not create a clinical need.
5. Cold chain and beyond-use dates. A pharmacy vial has a short beyond-use date, must stay refrigerated and is punctured repeatedly; FDA's page also records complaints about products shipped at the wrong temperature.

None of this makes a vial from a licensed pharmacy equivalent to a research vial bought online, which has no pharmacy, no label with a concentration, no beyond-use date and no legal basis at all.

Legal status in the United States, 2026

Tirzepatide is a legal, approved drug; only the compounded copies are in question. The dates match our legal tracker, which is updated as FDA acts.

• During the shortage (2022 to 2024), 503A pharmacies and 503B facilities could compound copies in volume. Most of the telehealth market was built then.
• December 19, 2024: FDA declared the shortage resolved; grace periods ended February 18, 2025 (503A) and March 19, 2025 (503B). Since then a compounded version is legal only for an individual patient whose documented clinical need the approved product cannot meet, never as a marketed copy (FDA GLP-1 concerns page).
• March 3, 2026: warning letters to 30 telehealth companies over the marketing of compounded GLP-1s (FDA 2026); on March 31, a letter to a vendor selling tirzepatide and retatrutide with research-use labels.
• May 1, 2026: a Federal Register proposal to keep tirzepatide, semaglutide and liraglutide off the 503B clinical-need list (Federal Register, May 2026); as of October 2026 still a proposal.
• June 16, 2026: 25 more letters to companies marketing compounded semaglutide and tirzepatide, 55 for the year.
• August 24, 2026: letters to five online vendors selling tirzepatide and other peptides as research chemicals, citing their dosing guides, calculators and bundled bacteriostatic water as evidence of drug intent.
• State law adds a layer: the prescriber must be licensed where you are, state boards license and inspect the pharmacies, and some states restrict which compounded products may be shipped in.

Legitimate program or copy-marketing operation?

The 2026 warning letters double as a checklist, because FDA quoted the marketing it objected to: claims that a product "contains the active pharmaceutical ingredient in Wegovy," descriptions such as "generic Zepbound," statements that "this FDA-approved treatment promotes safe, effective weight loss" or was "clinically studied and shown to deliver powerful results," and company-branded labels implying the telehealth firm compounded the drug itself. FDA's position is that compounded drugs are not FDA-approved, are not generics and were not evaluated for safety or effectiveness, so promotion implying otherwise makes them misbranded (Foley 2026).

Who should not take compounded tirzepatide

The label's contraindications apply to every form of the drug: a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, and a prior serious hypersensitivity reaction to tirzepatide. The label also advises against use in severe gastroparesis, says to stop the drug when a pregnancy is recognized, and tells people using oral contraceptives to add a barrier method for four weeks after starting and after each dose increase (Zepbound label). Prior pancreatitis, active gallbladder disease, diabetic retinopathy and insulin or sulfonylurea use call for a specialist conversation rather than a telehealth form.

Two more groups should not use the compounded version specifically: anyone who cannot reliably do the units arithmetic, read a syringe and keep a vial refrigerated, and anyone whose only reason for choosing it over the brand is price, because since 2024 that is not a legal basis for the prescription and, at current brand pricing, often not much of a financial one.

Bottom line

Tirzepatide is one of the best-evidenced weight-loss drugs ever approved, and compounded tirzepatide borrows all of that evidence while contributing none. What the vial adds is uncertainty about its contents and arithmetic that has put people in hospital; what it subtracts is a price advantage now down to a few hundred dollars a year at the doses most people take. In October 2026 the legal version exists for a patient with a documented reason the brand will not do, prescribed by a clinician licensed in their state and filled by a named pharmacy. For most other people the honest comparison is no longer compounded versus nothing; it is a compounded vial against a $299 to $449 Zepbound vial with a verified label, and the second is the easier case to make.

Frequently asked questions

+−What is compounded tirzepatide?

It is the same active ingredient as Mounjaro and Zepbound, bought as a bulk powder and dissolved into a multi-dose vial by a compounding pharmacy on a clinician's prescription. Unlike the brand pens, no compounded vial has been reviewed by FDA for potency, purity or sterility, and the only clinical trials of tirzepatide were run with the approved product. Since the shortage ended in December 2024, a pharmacy may prepare it only for a patient with a documented clinical need that Mounjaro or Zepbound cannot meet.

+−Is compounded tirzepatide safe?

The drug itself has a well-documented safety profile from the brand trials: mostly gastrointestinal side effects, plus rarer risks such as pancreatitis, gallbladder disease and a boxed warning about thyroid C-cell tumors seen in rats. The compounded version adds risks the brand does not have: the vial's content is unverified, and the dose must be drawn in syringe units from a concentration printed on the label. FDA has logged hundreds of adverse-event reports for compounded tirzepatide and has described overdoses of 5 to 20 times the intended dose from vial dosing errors. A compounded vial from a licensed, named pharmacy with a clear label is a different product from a research vial sold online.

+−What is the starting dose of compounded tirzepatide?

There is no separate dosing schedule for the compounded product; legitimate prescribers follow the Zepbound label. That means 2.5 mg once a week for four weeks, then 5 mg, with further increases of 2.5 mg at intervals of at least four weeks up to a maximum of 15 mg. The 2.5 mg dose is for starting treatment and is not an approved maintenance dose. From a 10 mg per mL vial, 2.5 mg is 0.25 mL, or 25 units on an insulin syringe.

+−How much does compounded tirzepatide cost?

In October 2026, most telehealth programs charge $180 to $300 a month, with a full range of about $99 to $399; the cheapest prices require 6- to 12-month commitments and apply to the lowest dose. Brand Zepbound vials cost $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5 to 15 mg through the manufacturer's self-pay program with on-time refills, so the compounded discount is now small at low doses and perhaps $100 to $200 a month at the top doses.

+−Are compounded GLP-1s going away?

The legal basis for compounding them in volume ended when FDA declared the tirzepatide shortage resolved on December 19, 2024 (grace periods ran to February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities). Patient-specific compounding for a documented need remains legal. In 2026 FDA sent 55 warning letters to telehealth companies over how compounded GLP-1s were marketed and, on May 1, 2026, proposed keeping tirzepatide, semaglutide and liraglutide off the list of substances outsourcing facilities may use. Expect the market to keep shrinking, not to disappear overnight.

+−Where can I buy tirzepatide?

You cannot buy it; it is a prescription drug. A clinician licensed in your state prescribes it after an evaluation, and either a retail pharmacy dispenses Mounjaro or Zepbound (including Zepbound vials through the manufacturer's self-pay program) or, when a documented clinical need justifies it, a licensed compounding pharmacy prepares it. Websites that sell tirzepatide vials without a prescription, often labeled for research use, are selling an unapproved drug, and FDA sent warning letters to such vendors in March and August 2026.

+−How does compound tirzepatide work?

Exactly like the brand, as long as the vial contains what its label says. Tirzepatide activates the receptors for two gut hormones, GIP and GLP-1. That increases insulin release when blood sugar is high, lowers glucagon, slows stomach emptying and reduces appetite, so people eat less without trying. In the phase 2 trial the dual agonist produced more weight loss and better glucose control than a GLP-1-only drug, dulaglutide.

+−Is tirzepatide a peptide?

Yes. It is a synthetic peptide of 39 amino acids based on the sequence of human GIP, with two unnatural amino acids for stability and a fatty-acid chain that binds albumin and stretches its half-life to about five days, which is what makes once-weekly injection possible. It is sold alongside wellness peptides such as sermorelin, but unlike most of them it is an FDA-approved drug with large trials.

+−Can I get tirzepatide prescribed online?

Yes, through telehealth, provided the clinician is licensed in the state where you are during the visit and performs a real evaluation. Many programs prescribe brand Zepbound vials and send the prescription to the manufacturer's pharmacy; others prescribe compounded tirzepatide, which is legal only with a documented reason the approved product cannot be used. A program that offers everyone the compounded version at a discount, or describes it as the same as Zepbound, is doing what FDA's 2026 warning letters targeted.

+−Is compounded tirzepatide the same as Zepbound?

The intended active ingredient is the same molecule, which is why the pharmacy may legally use it at all. The product is not the same: Zepbound is made in FDA-inspected plants, tested for potency and sterility, and delivered in a pen or a pre-measured vial, while a compounded vial is prepared by a pharmacy at a concentration of its choosing and has never been tested by FDA. FDA's 2026 letters specifically objected to marketing that called compounded products 'generic Zepbound' or implied they contained the approved product.

Sources

1. StudyJastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-16. (2022)
2. StudyGarvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402:613-26. (2023)
3. StudyAronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36. (2025)
4. StudyFrías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med 2021;385:503-15. (2021)
5. StudyJastreboff AM et al. Tirzepatide for obesity treatment and diabetes prevention (SURMOUNT-1, 176 weeks). N Engl J Med 2025;392:958-71. (2025)
6. StudyAronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. (2024)
7. StudyFrias JP et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 2018;392:2180-93. (2018)
8. StudyMcCall KL et al. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA Adverse Event Reporting System. Expert Opin Drug Saf 2026;25:581-8. (2026)
9. LabelEli Lilly. Zepbound (tirzepatide) injection, for subcutaneous use: prescribing information, revised August 2026 (DailyMed). (2026)
10. RegulatoryFDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss (shortage resolution, compounding after resolution, dosing errors, adverse-event reports).
11. RegulatoryFDA. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. July 26, 2024. (2024)
12. NewsDrug Discovery and Development. FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide (990 and more than 730 reports as of May 31, 2026). August 24, 2026. (2026)
13. RegulatoryFDA. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. Press announcement, March 3, 2026. (2026)
14. NewsFoley and Lardner. GLP-1 compliance: FDA targets telehealth marketing in 30 new warning letters. March 12, 2026. (2026)
15. RegulatoryFederal Register. List of bulk drug substances for which there is a clinical need under section 503B: FDA proposes not to include semaglutide, tirzepatide and liraglutide. May 1, 2026. (2026)